Development, Implementation, and Preliminary Evaluation of a Pneumonia Treatment Quality Audit & Feedback System in an ICU (DIPLOMAT-ICU)

Annick Sévigny, PharmD; William Nevers, B.Sc. Pharm, ACPR, PharmD; Anthony Amadio, B.Sc.Pharm, ACPR, PharmD; Jessica Beach, B.Sc.Pharm, ACPR, PharmD; Sean Gorman, B.Sc.Pharm, ACPR, PharmD; Ryan Foster, MD FRCP(C)

Background

Pneumonia is the most common type of infection in the intensive care unit (ICU) and the leading cause of death from infectious disease.

Development of Quality Indicators (QIs) allows for measurement and internal benchmarking in order to monitor and improve patient care.

Audit & Feedback is the capturing of an individual's or group's performance over a specified period of time, which is then provided to the individual(s). The purpose is to provide the recipient(s) with awareness to ultimately increased compliance with desired practice.

Objectives

- To evaluate the end-user satisfaction with feedback reports describing ICU treatment of pneumonia;
- To evaluate end-user usability of feedback reports;
- To evaluate end-user perceptions of whether feedback reports help change prescribing practices for pneumonia, and;
- Using the piloted QIs, to describe the initial management practice, de-escalation practice, and duration of therapy for pneumonia in the ICU.

Methods

Design


- Quality improvement study:
 - Development of QIs and feedback preference by end-users
 - Implementation of Audit & Feedback (November 1st, 2019 to March 31st, 2020)
 - Evaluation of Audit & Feedback through 3 an end-user survey (Qualtrics[™])

Setting:

Kelowna General Hospital (KGH) ICU Inclusion:

End-users: ICU Physicians having 1 or more years of experience in the ICU; willingness to participate; no conflict of interest with the study (n=9).





(I think the reports are usable)

Strongly Disagree	Some	what Disagree	Neutral	Somewhat	Agree	Agree	Strongly Agre	е	
In terms informing my antibiotic decision-ma	aking								
For other rea	sons								
	1	0	1	Number of Re	2 Snonse	3 s (n=5)	4	5	

Figure 3. End-User Survey Results – Practice Char (Based on the reports from the audit and feedback for antil Strongly Disagree Disagree Somewhat Disagree Neut The report will change my practice for antibiotic decision making We may overuse meropenem We may overuse piperacillin-tazobactam We may underuse piperacillin-tazobactam We may treat antibiotics for too long We may not treat with antibiotics for long enough We may not de-escalate to narrow spectrum as often as we should We de-escalate to narrow spectrum adequately

anging ibiotic use for pneumonia in the ICU I think)											
itral	Somew	hat Agree	Agree	Strongly Agree							
1	1 (C 2	 L :	2	3 4						
Number of Responses (n=5)											


Figure 4. Example QI #1: Antibiotic Regimen **Initiated for CAP** Ceftriaxone 20% 40% 60% 80% 100%

- Overall, n=23
 - Dr. A, n=6
 - Dr. B, n=6
 - Dr. C, n=3
 - Dr. D, n=2
 - Dr. E, n=1
 - Dr. F, n=1
 - Dr. G, n=1
 - Dr. H, n=1
 - Dr. l, n=1
 - Dr. J, n=1

Discussion Strengths: prescribers Limitations:

Conclusion

End-users were satisfied by the feedback, but found its usability and perception to change prescribing practice uncertain.



Established feedback preferences with end-users Pragmatic, real world data collected by clinical pharmacists as part of usual pharmaceutical care QIs are descriptive rather than evaluative Comparative audit and feedback among different

Failure to recruit all physicians to complete survey Distribution of QIs was large because of several physicians

QIs are not validated

Implication for Practice:

Feedback was perceived as satisfactory Greater context may improve usability and perceptions of whether feedback reports help change prescribing practice **Future Initiative/Research** Implementation of regular Audit & Feedback

Develop proven intervention

Expanded qualitative research

Development guideline-derived consensus QIs.